Global EditionASIA 中文双语Français
Home / World / Americas

US drugmaker Eli Lilly pauses antibody trial over safety concerns

Xinhua | Updated: 2020-10-14 06:15
Share - WeChat
FILE PHOTO: Eli Lilly logo is shown on one of the company's offices in San Diego, California, US, September 17, 2020. [Photo/Agencies]

WASHINGTON - US drugmaker Eli Lilly said Tuesday it has paused its trial of a combination antibody treatment for COVID-19 for safety reasons.

The company said the trial's Data Safety Monitoring Board (DSMB), an independent group of medical experts who monitor clinical trials, recommended the pause.

"The trial, evaluating Lilly's investigational neutralizing antibody as a treatment for COVID-19 in hospitalized patients, is sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH)," a Lilly spokesperson said in a statement.

"Lilly is supportive of the decision by the independent DSMB to cautiously ensure the safety of the patients participating in this study," said the statement.

Neither Eli Lilly nor the NIAID, which is sponsoring the trial, have described the safety issue that prompted the decision to pause the study.

Most Viewed in 24 Hours
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349